MedPath

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
-
Market Cap
-
Website

The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children

Phase 1
Withdrawn
Conditions
Herpes Simplex
Chickenpox
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registration Number
NCT00001054

Safety and Effectiveness of CD4-IgG2 in HIV-Positive Children

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
12
Registration Number
NCT00000876
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States

and more 5 locations

A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children

Phase 2
Completed
Conditions
Bacterial Infections
Pneumonia, Pneumocystis Carinii
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
690
Registration Number
NCT00000811
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Saint Christopher's Hosp for Children, Philadelphia, Pennsylvania, United States

๐Ÿ‡ต๐Ÿ‡ท

San Juan City Hosp, San Juan, Puerto Rico

๐Ÿ‡บ๐Ÿ‡ธ

Texas Children's Hosp / Baylor Univ, Houston, Texas, United States

and more 72 locations

Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients

Phase 3
Terminated
Conditions
HIV Infections
Pneumonia, Pneumocystis Carinii
First Posted Date
2001-08-31
Last Posted Date
2021-11-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
240
Registration Number
NCT00000730
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Julio Arroyo, West Columbia, South Carolina, United States

Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma

Phase 1
Completed
Conditions
Sarcoma, Kaposi
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
24
Registration Number
NCT00000660
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Mem Sloan - Kettering Cancer Ctr, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

San Francisco Gen Hosp, San Francisco, California, United States

and more 3 locations

A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
20
Registration Number
NCT00000667
Locations
๐Ÿ‡บ๐Ÿ‡ธ

NY Univ. HIV/AIDS CRS, New York, New York, United States

Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
54
Registration Number
NCT00000646
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Case CRS, Cleveland, Ohio, United States

๐Ÿ‡บ๐Ÿ‡ธ

Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States

Mycophenolate Mofetil and Abacavir Treatment in HIV Patients With Failed Anti-HIV Treatment

Phase 2
Withdrawn
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registration Number
NCT00021489

The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
140
Registration Number
NCT00001074
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Julio Arroyo, West Columbia, South Carolina, United States

๐Ÿ‡บ๐Ÿ‡ธ

Johns Hopkins Hosp, Baltimore, Maryland, United States

๐Ÿ‡บ๐Ÿ‡ธ

Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States

and more 15 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath